Post DCGI approval, Gennova to produce 40-50 lakh doses of GEMCOVAC-19 vaccine

New Delhi: Having received the Emergency Use Authorization (EUA) for its mRNA vaccine, GEMCOVAC-19, against COVID 19 from the office of the Drugs Controller General of India (DCGI), Gennova Biopharmaceuticals now aims to produce around 40 – 50 lakhs of doses per month. The company expects the capacity to be quickly doubled if required to do so.

GEMCOVAC-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world. These vaccines are highly efficacious because of their inherent capacity of being translated into the protein structure inside the cell cytoplasm.

mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. Notably, this technology provides flexibility to quickly tweak the vaccine for any existing or emerging variants of the virus and this technology platform will empower India to be pandemic ready.

Gennova’s GEMCOVAC-19 has reached the primary end point of the Phase III clinical trial. The clinical data was evaluated by the Central Drugs Standard Control Organisation (CDSCO). The vaccine was found to be safe, well-tolerated and immunogenic.

A subsidiary of Emcure Pharmaceuticals, Gennova aims at providing sustainable access to low-and middle-income countries around the world to the vaccine to blunt the spread of pandemic.